Lunit to join Summit Therapeutics on cancer drug AI research
Lunit will support the development of Ibonesimab, a next-generation immuno-cancer drug, alongside U.S. biotech Summit Therapeutics.
By Standard Topic. AI-generated from the reporting listed under Coverage. Published . Updated .
This story is no longer being updated. It reflects reporting up to .
What happened
Lunit will support the development of Ibonesimab, a next-generation immuno-cancer drug, alongside U.S. biotech Summit Therapeutics. The partnership includes AI research aimed at developing new cancer treatments. Lunit's stock hit its daily ceiling during early trading.
Why it matters
The deal extends Lunit's AI work into the development of a new cancer drug.
Coverage
- Medical artificial intelligence (AI) company Lunit hit the upper limit in early trading on the news .. (김현정)
- Medical artificial intelligence (AI) company Lunit will support the development of the next-generati.. (왕해나)
More from Technology & AI
- China puts humanoid robots to work serving food and sorting parcels
- Newsom proposes sweeping AI safety rules for Washington
- Google releases Gemini 4 Neon AI model with million-token context
- Microsoft and Intel widen their cloud chip partnership
- Google DeepMind rolls out Genie 4 to select subscribers
- AI helped AMD shorten chip design work, OpenAI says